This trial is evaluating whether VRC-MALMAB0114-00-AB will improve 1 primary outcome and 2 secondary outcomes in patients with Malaria. Measurement will happen over the course of Through 24 weeks after product administration.
This trial requires 32 total participants across 6 different treatment groups
This trial involves 6 different treatments. VRC-MALMAB0114-00-AB is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"This answer is that, like people having a stroke, people having a fever should be told that their symptoms may be due to malaria, because only a few other conditions (e.g., brain cancer, liver cancer, heart disease, and HIV) present similarly in people of similar ages and with similar clinical features in areas where malaria is common without prompt medical attention. #1\n" - Anonymous Online Contributor
"Malaria is caused by parasites in the family of "Plasmodium spp".\n\nMost types of infection are made worse by climate and can be treated with drugs for preventive or antiprotective measures.\n\nVaccines are available to prevent cholera and typhoid fever." - Anonymous Online Contributor
"Malaria is not a curable disease. If treatment is effective, there may be little to no relapse in cured patients. There is a chance that the malaria parasite's virulence will be reduced sufficiently to make it asymptomatic but not necessarily eradicated. At this point, there is no evidence that the malaria parasite could be a potentially lethal disease, such as cholera. This is also the case with the more deadly malaria plasmodium vivax parasite. Some treatments which have been recommended for the treatment of malaria can cure and prevent this disease. Most of the cures for malaria are based on one method or another, but there are other treatments which can be used to provide symptomatic relief." - Anonymous Online Contributor
"About 300,000 American travelers encounter malaria annually, and about 12,000 experience an episode of severe or nonsevere malaria. The incidence of severe malaria due to Plasmodium falciparum is significantly lower in the United States than elsewhere, but there is a substantial burden of nonsevere malaria." - Anonymous Online Contributor
"Malaria is a parasitic infection that mainly affects people living in tropical lowland areas. Most cases are due to Plasmodium falciparum malaria (about 80%), but other forms also occur. The disease is often asymptomatic and is transmitted by the bite of an infected femaleAnopheles mosquito. It causes high morbidity and mortality among children and pregnant women and is increasingly being diagnosed in adults, but still has a very poor prognosis." - Anonymous Online Contributor
"What are the most common treatments for malaria? A review of available randomized controlled trials confirms that artemsinin-based combination treatment seems the safest. Artemisinin monotherapy is still being recommended, mainly on the basis of convenience. In developing countries the use of artemisinin and its compounds has spread the net of great benefits. Also, at present, the combination drug artesunate with amodiaquine is suggested for the treatment of complicated malaria. However, artesunate is not recommended for all malaria cases except in severely depleted health facilities." - Anonymous Online Contributor
"For the first time, this study found a significant increase in the frequency of malaria in patients with first degree relatives with an odd ratio of 1.62 (P>0.05), compared with patients without relatives. The mean parasite asexual multiplication rate (mean AR) was 2.7 in relatives vs. 6.6 (SD [1.6]) in nonrelatives. The risk of the development of clinical falciparum malaria in relatives was four times higher than that in nonrelatives after adjusting for confounding factors, with the log-rank hazard ratio of 2.64 (95% CI:1.05−6.44, P=0.037)." - Anonymous Online Contributor
"The average age of first malaria infection is 6 months, at around the age of the first serious infection. By contrast malaria prevalence is highest among younger children. There is thus a considerable gap between current and desired age-specific prevalence, which suggests that the timing of malaria prevention campaigns could be revised." - Anonymous Online Contributor
"In this second-line treatment (as opposed to first-line) scenario, Vrc-malmab0114-00-ab + doradeteleb (single-agent regimen) was found to significantly increase PFS rates compared with V-d+F and V-d+AB/Artemether/Artesunate combination. Results from a recent clinical trial suggest that the addition of Vrc-malmab0114-00-ab may enhance the activity of Artesonis plus Artetex, which showed significant prolongation of PFS rates as compared with Artesonis alone. Further clinical studies should assess the added benefit of artemisinin combination therapies." - Anonymous Online Contributor
"In the treatment of non-malarial diseases, patients with the following medical conditions were usually treated with Vrc-malmab0114-00-Ab: nephrosis, kidney impairment/failure, kidney disease, chronic kidney disease, malignant neoplasm, heart diseases, and neurological diseases. However, even though many other medical conditions were treated, no data could be provided due to insufficient number of data for the treatment with this monoclonal antibody because only a small portion was reported in clinical trial. Moreover, there was no data on treatment of other medical conditions except nephrosis." - Anonymous Online Contributor
"VRC-malmab is effective in subjects with subclinical cerebral malaria, despite the low sensitivity, specificity and positive predictive value of VRC-malmab. A significant number of subclinical cerebral malaria subjects show no change in Hb after treatment with VRC-malmab. A larger study will help to verify these findings." - Anonymous Online Contributor
"At current rates of morbidity and mortality, malaria and other infectious diseases will pose increasingly serious threats to human health in the 21st century. Malaria will be a particularly serious threat in the tropics because the impact of poor health on poverty and growth will be enormous. The disease burden that malaria poses on countries’ most vulnerable populations, such as children and pregnant women, is a major reason why a concerted global response is urgently needed to really cut the burden of parasitic diseases." - Anonymous Online Contributor